erratum “Update in the Treatment of Venous Thromboembolism”

The publisher regrets a dosage error in Table [1] in the above article in Seminars in Respiratory and Critical Care Medicine, Volume 29, Number 1, 2008, p. 42.

Dosage should state q.d. (once daily) not q.i.d. (four times daily).

Table [1] with the correct dosage appears below.

Table 1 Evidence-Based Therapies Available in the United States for the Treatment of Venous Thromboembolism** LMWH Dose Comments Dalteparin 100 IU/kg SQ b.i.d. or 200 IU SQ q.d. FDA-approved using q.d. dose for long-term therapy in cancer patients with DVT (25% dose reduction after 1st month of treatment) Enoxaparin 1.0 mg/kg SQ b.i.d. (studied in outpatients with/without PE) 1.5 mg/kg SQ q.d. (studied in inpatients with/without PE) FDA-approved Tinzaparin 175 IU/kg SQ q.d. (acute treatment of DVT with/without PE) FDA-approved for treatment; studies done in hospitalized patients PENTASACCHARIDE Fondaparinux 7.5 mg SQ q.d. FDA-approved for treatment of both DVT and PE (use 5 mg SQ q.d. for < 50 kg and 10 mg SQ q.d. for > 100 kg) UFH SQ (non–dose adjusted) 333 IU/kg SQ initially, followed by 250 IU/kg SQ q12h Nonmonitored dose as per Kearon et al.16 Should be reserved as second-line therapy because published experience is limited. IV (weight-based nomogram) 80 U/kg initial bolus, followed by 18 U/kg/h maintenance Use weight-based nomogram, adjusted to achieve aPTT 1.5 to 2.5 × control. aPTT, activated partial thromboplastin time; DVT, deep vein thrombosis; IV; FDA, U.S. Food and Drug Administration; intravenous; LMWH, low molecular weight heparin; PE, pulmonary embolism; SQ, subcutaneous; UFH, unfractionated heparin. At least 5-day overlap with vitamin K antagonist until stable international normalized ratio (> 2.0) achieved.